Op vrijdag heeft BMO Capital Markets het koersdoel voor de aandelen van Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) verhoogd van $520 naar $545, terwijl het Outperform-advies werd gehandhaafd.

Vertex CEO Jeffrey Leiden has offered an olive branch to negotiators in the UK that could see the cystic fibrosis drug Orkambi finally supplied to patients in England.

A Waltham biotech focused on cystic fibrosis and a Boston biotech led by serial founder Gary Glick are the first ...

The NICE-Vertex saga continued this month with Vertex’s CEO Jeffrey Leiden hinting at ‘new ideas’ to bring cystic fibrosis drug Orkambi to UK patients. Leiden said that he is to meet with ...

At Vertex Pharmaceuticals, we’re fortunate to work with talented scientists like Leo Vo, a researcher at our Jeffrey Leiden Center for Biologics, Cell & Genetic Therapies in Boston. Leo’s ...

Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed both its biotech peers and the broader market since 2022. The company dominates the cystic fibrosis market and is ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $440.68, marking a -0.72% move from the previous day. Vertex (VRTX) has received quite a bit of attention from Zacks.com ...

VRTX insiders have traded $VRTX stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales. Here’s a ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...